Mind-NRG

About:

Mind-NRG develops peptidic neurotrophic factors for psychiatric and neurologic diseases.

Website: http://www.mind-nrg.com/

Top Investors: Index Ventures, Limburgse Reconversie Maatschappij

Description:

Mind-NRG, based out of Switzerland, is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood - brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 will be developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia. Mind-NRG will initially focus on conducting in vitro and in vivo experiments to further explore the mechanism of action of the peptide and to assess the activity of NRG-101 in a variety of relevant disease models.

Total Funding Amount:

$23.7M

Headquarters Location:

Geneva, Geneve, Switzerland

Founded Date:

2010-01-01

Contact Email:

info(AT)mind-nrg.com

Founders:

Gage Tarrant

Number of Employees:

1-10

Last Funding Date:

2013-09-04

IPO Status:

Private

Industries:

© 2025 bioDAO.ai